Association between fetal growth restriction and late complications in long-term survivors of pediatric acute lymphoblastic leukemia

Yıl 2025, Cilt: 50 Sayı: 3, 561 - 564, 30.09.2025

Burçak Kurucu , Gürses Şahin

https://doi.org/10.17826/cumj.1618661

Öz

Purpose: This study aimed to investigate the association between fetal growth restriction (FGR) and the development of late complications in long-term survivors of pediatric acute lymphoblastic leukemia (ALL).
Materials and Methods: This study enrolled 108 long-term survivors of pediatric ALL, who were subsequently divided into two groups. Group 1 consisted of 48 patients with a history of FGR, while Group 2 included 60 patients with normal fetal growth. The groups were compared based on demographic characteristics, treatment status, duration of remission, maternal and paternal age at conception, maternal weight gain during pregnancy, parental smoking and alcohol use, and the incidence of late complications.
Results: No significant association was found between the groups regarding treatment status, demographic factors, remission duration, or familial risk factors. However, the number of late complications was statistically significantly higher in Group 1 (37/48, 77.1%) compared to Group 2 (18/60, 30.0%). The most frequently observed late complications were endocrine (47/108), cardiac (21/108), osseous (18/108), metabolic (8/108), and neurological (3/108).
Conclusion: ALL treatment may induce late complications by affecting various systems and tissues through oxidative mechanisms, particularly in patients with a history of FGR. Our findings may aid clinicians in predicting the risk of late complications and developing early prevention strategies for ALL survivors with a history of FGR.

Anahtar Kelimeler

Fetal growth restriction , acute lymphoblastic leukemia , late complications , childhood , long-term survivors

Pediatrik akut lenfoblastik lösemi hastalarının uzun dönem sağ kalanlarında fetal büyüme geriliğinin geç komplikasyonlarla ilişkisi

Öz

Amaç: Pediatrik akut lenfoblastik lösemi’nin(ALL) 'uzun dönem sağ kalanlarında fetal büyüme geriliği (FBG) ile geç komplikasyonlar arasındaki ilişkiyi araştırdık.
Gereç ve Yöntem: Çalışmada, pediatrik ALL hastalarından uzun dönem sağ kalan 108 hasta ; FBG'ye (grup 1, n=48) ve normal büyümeye (grup 2, n=60) göre iki gruba ayrıldı. Gruplar tedavi durumu, demografik özellikler, remisyon süresi, maternal gebelik yaşı, paternal gebe kalma yaşı, gebelik sırasında maternal kilo alımı, ebeveynlerin sigara ve alkol tüketimi ve geç komplikasyonlar açısından değerlendirildi.
Bulgular: Çalışmada hastaların tedavi durumu, demografik faktörler, remisyon süresi ve ailevi risk faktörleri arasında bir ilişki bulunmadı. Geç komplikasyon sayısı grup 1'de (37/48, %77,1) grup 2'ye (18/60, %30,0) göre istatistiksel olarak daha yüksekti (p<0,001). En sık görülen geç komplikasyonlar endokrin (47/108), kardiyak (21/108), osseöz (18/108), metabolik (8/108) ve nörolojik (3/108) komplikasyonlardı.
Sonuç: ALL tedavisi, özellikle FBG öyküsü olan hastalarda, oksidatif mekanizmalarla, çeşitli sistem ve dokuları etkileyerek geç komplikasyonlara neden olabilir. Çalışmamız, FBG öyküsü olan sağ kalanlarda geç komplikasyon riskini ve erken önlemeyi tahmin etmede klinisyenlere fayda sağlayacaktır.

Anahtar Kelimeler

Fetal büyüme geriliği , akut lenfoblastik lösemi , geç komplikasyonlar , çocukluk çağı , uzun dönem sağ kalanlar

Kaynakça

• Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukemia. Lancet. 2013;381:1943-55.
• Lee JW, Cho B. Prognostic factors and treatment of pediatric acute lymphoblastic leukemia. Korean J Pediatr. 2017;60:129-37.
• Smith MA, Seibel NL, Altekruse SF, Ries LA, Melbert DL, O'Leary M et al. Outcomes for children and adolescents with cancer: challenges for the twentyfirst century. J Clin Oncol. 2010;28:2625-34.
• Essig S, Li Q, Chen Y, Hitzler J, Leisenring W, Greenberg M et al. Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2014;15:841-51.
• Al-Mahayri ZN, AlAhmad MM, Ali BR. Long-term effects of pediatric acute lymphoblastic leukemia chemotherapy: Can recent findings inform old strategies? Front Oncol. 2021;11:710163.
• Devaskar SU, Chu A. Intrauterine growth restriction: Hungry for an answer. Physiology. 2016;31:131-46.
• Baschat AA. Neurodevelopment after fetal growth restriction. Fetal Diagn Ther. 2014;36:136-42.
• Longo S, Bollani L, Decembrino L, Di Comite A, Angelini M, Stronati M. Short-term and long-term sequelae in intrauterine growth retardation (IUGR). J Matern Fetal Neonat Med. 2013;26:222-25.
• Eroglu H, Turgal M, Senat A, Karakoc G, Neselioglu S, Yucel A. Maternal and fetal thiol/disulfide homeostasis in fetal growth restriction. J Matern Fetal Neonat Med. 2021;34:1658-65.
• Tudela F, Lambertini L, Peña J, Jones R, Mystal E, Ma Y et al. 465: placental mitochondrial DNA mutation rate: a new association with intrauterine growth restriction (IUGR). Am J Obstet Gynecol. 2016;214:255-6.
• Eroglu N, Yoldas T, Bilgin B, Yesil S, Fettah A, Sahin G et al. Intrauterine growth retardation is a risk factor for anthracycline toxicity. Pediatr Hematol Oncol. 2021;38:497-503.
• Yoldas T, Yesil S, Karademir S, Şahin G, Arman Örün U, Doğan V et al. Evaluation of long-term cardiac side effects of anthracycline chemotherapy by conventional and non-conventional echocardiographic methods in childhood cancer survivors. Cardiol Young. 2019;29:904-9.
• Kızılocak H, Okcu F. Late effects of therapy in childhood acute lymphoblastic leukemia survivors. Turk J Haematol. 2019;36:1-11.
• Che H, Long D, Sun Q, Wang L, Li Y. Birth weight and subsequent risk of total leukemia and acute leukemia: A systematic review and meta-analysis. Front Pediatr. 2021;9:722471.
• Dockerty JD, Draper G, Vincent T, Rowan SD, Bunch KJ et al. Case-control study of parental age, parity and socioeconomic level in relationship to childhood cancers. Int J Epidemiol. 2001;30:1428-37.
• Cao Y, Lu J, Lu J. Paternal smoking before conception and during pregnancy is associated with an increased risk of childhood acute lymphoblastic leukemia: A systematic review and meta-analysis of 17 case-control studies. J Pediatr Hematol Oncol. 2020;42:32-40.
• Mellemkjær L, Hasle H, Gridley G, Johansen C, Kjaer SK, Frederiksen K et al. Risk of cancer in children with the diagnosis immaturity at birth. Paediatr Perinat Epidemiol. 2006;20:231-7.
• Wang YF, Wu LQ, Liu YN, Bi YY, Wang H et al. Gestational age and childhood leukemia: A meta-analysis of epidemiologic studies. Hematology. 2018;23:253-62.
• Spector LG, Puumala SE, Carozza SE, Chow EJ, Fox EE, Horel S et al. Cancer risk among children with very low birth weights. Pediatrics. 2009;124:96-104.
• Paquette K, Coltin H, Boivin A, Amre D, Nuyt AM, Luu TM et al. Cancer risk in children and young adults born preterm: A systematic review and meta-analysis. PLoS One. 2019;14:0210366.
• Figueras F, Gratacos E. Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol. Fetal Diagn Ther. 2014;36:86-98.
• Sklar CA, Antal Z, Chemaitilly W, Cohen LE, Follin C, Meacham LR et al. Hypothalamic-pituitary and growth disorders in survivors of childhood cancer: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103:2761-84.
• Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev. 2002;16:225-43.
• Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist. 2004;10:293-310.
• Nam GE, Kaul S, Wu YP, Nelson RE, Wright J, Fluchel MN et al. A meta-analysis of body mass index of adolescent and adult survivors of pediatric acute lymphoblastic leukemia. J Cancer Surviv. 2015;9:412-21.
• Watsky MA, Carbone LD, An Q, Cheng C, Lovorn EA, Hudson MM et al. Bone turnover in long-term survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014;61:1451-6.
• van Atteveld JE, Pluijm SMF, Ness KK, Hudson MM, Chemaitilly W, Kaste SC et al. Prediction of low and very low bone mineral density among adult survivors of childhood cancer. J Clin Oncol. 2019;37:2217-25.
• Gurney JG, Kaste SC, Liu W, Srivastava DK, Chemaitilly W, Ness KK et al. Bone mineral density among long-term survivors of childhood acute lymphoblastic leukemia: results from the St. Jude Lifetime Cohort Study. Pediatr Blood Cancer. 2014;61:1270-6.
• Morel S, Leahy J, Fournier M, Lamarche B, Garofalo C, Grimard G et al. Lipid and lipoprotein abnormalities in acute lymphoblastic leukemia survivors [S]. J Lipid Res. 2017;58:982-93.
• Nathan PC, Wasilewski-Masker K, Janzen LA. Long-term outcomes in survivors of childhood acute lymphoblastic leukemia. Hematol Oncol Clin N Am. 2009;23:1065-82.
• Armenian SH, Armstrong GT, Aune G, Chow EJ, Ehrhardt MJ, Ky B et al. Cardiovascular disease in survivors of childhood cancer: Insights into epidemiology, pathophysiology, and prevention. J Clin Oncol. 2018;36:2135-44.
• Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voûte PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol. 2002;13:819-29.
• Goldsby RE, Liu Q, Nathan PC, Bowers DC, Yeaton-Massey A, Raber SH et al. Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2010;28:324-31.
• Fulbright JM, Raman S, McClellan WS, August KJ. Late effects of childhood leukemia therapy. Curr Hematol Malig Rep. 2011;6:195-205.
• Borgmann A, Zinn C, Hartmann R, Herold R, Kaatsch P, Escherich G et al. Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. Eur J Cancer. 2008;44:257-68.
• Mody R, Li S, Dover DC, Sallan S, Leisenring W, Oeffinger KC et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood. 2008;111:5515-23.
• Hijiya N, Hudson MM, Lensing S, Zacher M, Onciu M, Behm FG et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA. 2007;297:1207-15.
• Bhatia S, Sather HN, Pabustan OB, Trigg ME, Gaynon PS, Robison LL et al. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood. 2002;99:4257-64.